Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$95.02

0.43 (0.45%)

, JNJ

Johnson & Johnson

$139.75

1.59 (1.15%)

05:26
10/02/18
10/02
05:26
10/02/18
05:26

AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.

ABBV

AbbVie

$95.02

0.43 (0.45%)

JNJ

Johnson & Johnson

$139.75

1.59 (1.15%)

PFE

Pfizer

$44.28

0.205 (0.47%)

  • 03

    Oct

  • 03

    Oct

  • 10

    Oct

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 28

    Oct

  • 30

    Oct

ABBV AbbVie
$95.02

0.43 (0.45%)

09/10/18
BTIG
09/10/18
INITIATION
Target $32
BTIG
Buy
Voyager Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed Voyager Therapeutics (VYGR) with a Buy rating and a price target of $32, saying the company is an "attractive investment" based on its lead product for late-stage Parkinson's Disease patients and its "robust" adeno-associated viral technology platform. The analyst expects Voyager to be well served in its upcoming gene therapy market share competition and also cites the company's "productive FDA meetings"and the start of of a phase 2 trial. Shrader further notes that Voyager Therapeutics' latest Abbvie (ABBV) deal is a "vote of confidence" for its program.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $100
PIPR
Neutral
Piper more worried about AbbVie co-pay accumulator risk than California suit
While shares of AbbVie may move lower today on news of California's insurance regulator suing the company over promotion of Humira, a more fundamental potential drag on Humira remains the advent of co-pay accumulators, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst sees the California lawsuit as more headline risk than anything but thinks "it may nevertheless serve as a minor overhang on shares." He points out that new research this week by Drug Channels suggests that more than one-third of commercial lives are enrolled in plans that have implemented copay accumulators for 2018, higher than his prior best estimate of 17%. Raymond keeps a Neutral rating on AbbVie with a $100 price target.
09/19/18
FBCO
09/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's California lawsuit may have broader implications, says Credit Suisse
After the State of California has filed a lawsuit against AbbVie, accusing the company of paying kickbacks to doctors and using a network of nurses to illegally boost Humira prescriptions, Credit Suisse analyst Vamil Divan said he is "not surprised" by the stock's weakness given how leveraged it is to Humira sales and profit, and think there could be additional weakness as the story develops, especially if other states file similar lawsuits against the company. Additionally, he wonders how lawsuits like this may impact marketing practices across the industry. Divan maintains a cautious view on the stock with an Underperform rating and $85 price target, and says he continues to have concerns about the sustainability of Humira given the expected entry of multiple biosimilars in the EU next month expected biosimilar pressure in the U.S. starting in 2023.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
JNJ Johnson & Johnson
$139.75

1.59 (1.15%)

09/14/18
WELS
09/14/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $150 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Johnson & Johnson to $160 after the company hosted an investor call to provide an update on its Pharmaceuticals business. The analyst heard no strategic change to the business saying J&J maintains focus on its six key therapeutic areas and remains agnostic to the source of innovation. While the company did not provide 2019 guidance, management's tone came across as confident in the business outlook, Biegelsen tells investors in a research note. He keeps an Outperform rating on Johnson & Johnson.
08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Portola may be up 'somewhat' on Xarelto trial failure, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted the failure of Johnson & Johnson's (JNJ)MARINER study, which was examining Xarelto, a competing anticogulant to Portola's (PTLA) BevyxXa. MARINER's failure to demonstrate a statistically significant result of reducing symptomatic VTE or death due to VTE is expected by Harrison to send Portola shares up "somewhat," but he believes most investors had already lowered their expectations for the BevyxXa franchise after the Q2 report, making the impact modest. He maintains an Equal Weight rating on Portola shares, which are up 3% to $29 per share in early trading.
08/27/18
WBLR
08/27/18
NO CHANGE
WBLR
Outperform
Mariner failure removes potential Portola competition, says William Blair
William Blair analyst Matt Phipps says that while the failure of Johnson & Johnson's (JNJ) Mariner trial removes potential competition Portola Pharmaceuticals' (PTLA) Bevyxxa, which is positive, "significant work" is still needed to gain adoption of Bevyxxa in the United States. As such, the Mariner results do not significantly alter the near-term headwinds for Bevyxxa, Phipps tells investors in a research note. The analyst believes getting beyond the Mariner presentation allows investors to focus on the opportunity for Andexxa, which he still thinks is "significant." He points out that Portola remains on track to file the prior approval supplement for the second-generation manufacturing process of Andexxa in the coming days, which would provide sufficient supply for 1,000 hospitals in the United States and expansion into Europe. Phipps keeps an Outperform rating on Portola Pharmaceuticals, which is up 5% to $29.60 in premarket trading.
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
PFE Pfizer
$44.28

0.205 (0.47%)

10/01/18
JPMS
10/01/18
NO CHANGE
Target $46
JPMS
Overweight
Pfizer price target raised to $46 from $42 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Pfizer to $46 on a revisit of the company's story. The analyst sees a "meaningful shift" in the Pfizer narrative away from potential acquisitions to the company's organic growth prospects post the Lyrica patent expiration in 2019. While he expects the company's growth will slow in 2019/2020, he sees a "distinct re-acceleration" of sales and earnings growth for Pfizer in the 2021-2025 period. Schott believes shares of Pfizer can further re-rate if the Street gains further confidence in its "sustained topline growth and capital deployment opportunities." The analyst keeps an Overweight rating on the shares.
09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.
09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.
09/11/18
BARD
09/11/18
NO CHANGE
Target $85
BARD
Outperform
Exact Sciences price target raised to $85 from $74 at Baird
Baird analyst Catherine Ramsey Schulte raised her price target on Exact Sciences (EXAS) to $85 from $74 citing increased confidence in its partnership with Pfizer (PFE). She sees several different potential outcomes given different assumptions for Pfizer rep productivity and order rate increases. Schulte reiterated her Outperform rating on Exact Sciences shares.

TODAY'S FREE FLY STORIES

SNAP

Snap

$5.80

-0.74 (-11.32%)

12:20
01/16/19
01/16
12:20
01/16/19
12:20
Options
Heavy option flow in Snap Inc following downgrade »

Heavy option flow in Snap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
01/16/19
01/16
12:17
01/16/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
01/16/19
01/16
12:16
01/16/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$9.30

0.68 (7.89%)

, CRZBY

Commerzbank

$0.00

(0.00%)

12:05
01/16/19
01/16
12:05
01/16/19
12:05
Periodicals
ECB prefers Deutsche Bank merge with European rival, Bloomberg says »

The European Central Bank…

DB

Deutsche Bank

$9.30

0.68 (7.89%)

CRZBY

Commerzbank

$0.00

(0.00%)

UBS

UBS

$13.54

0.325 (2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$30.38

-0.29 (-0.95%)

12:04
01/16/19
01/16
12:04
01/16/19
12:04
Hot Stocks
eBay appoints Steve Wymer as SVP and Chief Communications Officer »

Steve Wymer is joining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$62.73

-5.73 (-8.37%)

12:00
01/16/19
01/16
12:00
01/16/19
12:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN falls -8.6% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$5.82

-0.72 (-11.01%)

12:00
01/16/19
01/16
12:00
01/16/19
12:00
Hot Stocks
Snap falls -11.0% »

Snap is down -11.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 03

    Mar

IAG

IAMGold

$3.18

-0.4 (-11.17%)

12:00
01/16/19
01/16
12:00
01/16/19
12:00
Hot Stocks
IAMGold falls -11.2% »

IAMGold is down -11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

SMTA

Spirit MTA REIT

$8.00

0.77 (10.65%)

12:00
01/16/19
01/16
12:00
01/16/19
12:00
Hot Stocks
Spirit MTA REIT rises 10.2% »

Spirit MTA REIT is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVC

Invacare

$5.62

0.66 (13.31%)

12:00
01/16/19
01/16
12:00
01/16/19
12:00
Hot Stocks
Invacare rises 12.9% »

Invacare is up 12.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$11.88

0.02 (0.17%)

12:00
01/16/19
01/16
12:00
01/16/19
12:00
Options
Barrick Gold calls active as positions are covered ahead of the expiration »

Barrick Gold calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$20.94

3.39 (19.32%)

12:00
01/16/19
01/16
12:00
01/16/19
12:00
Hot Stocks
First Data rises 19.4% »

First Data is up 19.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

JBLU

JetBlue

$17.42

0.27 (1.57%)

, UAL

United Continental

$86.43

5.2 (6.40%)

11:57
01/16/19
01/16
11:57
01/16/19
11:57
On The Fly
United soars after fourth quarter revenue beat as airline continues to take share »

Shares of United…

JBLU

JetBlue

$17.42

0.27 (1.57%)

UAL

United Continental

$86.43

5.2 (6.40%)

DAL

Delta Air Lines

$48.30

0.49 (1.02%)

AAL

American Airlines

$33.45

1.35 (4.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

  • 24

    Jan

  • 04

    Mar

MRT

MedEquities Realty Trust

$10.82

0.1 (0.93%)

11:56
01/16/19
01/16
11:56
01/16/19
11:56
Hot Stocks
Chicago Capital reports 6.65% passive stake in MedEquities Realty Trust »

Chicago Capital …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHUN

Phunware

$140.01

-6.97 (-4.74%)

11:55
01/16/19
01/16
11:55
01/16/19
11:55
Hot Stocks
Breaking Hot Stocks news story on Phunware »

Phunware Inc trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$55.80

0.79 (1.44%)

, ASH

Ashland

$76.00

1.425 (1.91%)

11:55
01/16/19
01/16
11:55
01/16/19
11:55
Conference/Events
Jefferies chemicals analyst to hold a group luncheon »

Chemicals Analyst…

DWDP

DowDuPont

$55.80

0.79 (1.44%)

ASH

Ashland

$76.00

1.425 (1.91%)

FMC

FMC Corporation

$79.70

0.52 (0.66%)

LTHM

Livent

$13.27

-0.135 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 31

    Jan

  • 12

    Feb

  • 12

    Feb

  • 11

    Mar

  • 28

    May

JNPR

Juniper

$28.14

0.03 (0.11%)

, IBM

IBM

$121.68

-0.07 (-0.06%)

11:53
01/16/19
01/16
11:53
01/16/19
11:53
Hot Stocks
IBM Services announces $325M agreement with Juniper »

IBM Services (IBM)…

JNPR

Juniper

$28.14

0.03 (0.11%)

IBM

IBM

$121.68

-0.07 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 07

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

SSNLF

Samsung

$0.00

(0.00%)

, NTDOY

Nintendo

$0.00

(0.00%)

11:53
01/16/19
01/16
11:53
01/16/19
11:53
Hot Stocks
'Pokemon GO' maker Niantic announces $245M in Series C financing »

Niantic, the developer…

SSNLF

Samsung

$0.00

(0.00%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHUN

Phunware

$140.01

-6.97 (-4.74%)

11:50
01/16/19
01/16
11:50
01/16/19
11:50
Hot Stocks
Breaking Hot Stocks news story on Phunware »

Phunware Inc trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWLO

Twilio

$99.80

-0.62 (-0.62%)

11:50
01/16/19
01/16
11:50
01/16/19
11:50
Options
Twilio calls lead puts nearly 3:1 as shares climb off morning lows »

Twilio calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 12

    Feb

TYME

Tyme Technologies

$3.47

-0.12 (-3.34%)

11:40
01/16/19
01/16
11:40
01/16/19
11:40
Options
Aggressive put buy in Tyme Technologies »

Aggressive put buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

BLK

BlackRock

$417.04

16.81 (4.20%)

11:34
01/16/19
01/16
11:34
01/16/19
11:34
Periodicals
Fake annual letter from BlackRock CEO sent to media outlets, Barron's says »

An email was sent to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 23

    Jan

  • 29

    Jan

  • 11

    Feb

PPG

PPG

$102.31

1.31 (1.30%)

11:30
01/16/19
01/16
11:30
01/16/19
11:30
Options
PPG Industries puts active ahead of earnings »

PPG Industries puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EADSY

Airbus

$0.00

(0.00%)

11:29
01/16/19
01/16
11:29
01/16/19
11:29
Periodicals
Airbus investing $300M for new A220 plant in Alabama, Reuters reports »

Airbus is investing $300M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BUD

AB InBev

$70.49

-2.04 (-2.81%)

, ACN

Accenture

$148.37

1.53 (1.04%)

11:29
01/16/19
01/16
11:29
01/16/19
11:29
On The Fly
Downgrades of IT Hardware sector, AB Inbev among today's top analyst calls »

Check out today's top…

BUD

AB InBev

$70.49

-2.04 (-2.81%)

ACN

Accenture

$148.37

1.53 (1.04%)

HPE

HP Enterprise

$14.08

-0.37 (-2.56%)

NTAP

NetApp

$61.25

-1.23 (-1.97%)

NTNX

Nutanix

$49.83

1.075 (2.20%)

TDC

Teradata

$43.09

1.35 (3.23%)

AAPL

Apple

$155.13

2.09 (1.37%)

AVGO

Broadcom

$255.49

-1.02 (-0.40%)

CRUS

Cirrus Logic

$36.22

0.74 (2.09%)

QRVO

Qorvo

$61.91

0.36 (0.58%)

SWKS

Skyworks

$69.44

0.99 (1.45%)

SYNA

Synaptics

$39.79

0.15 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 29

    Jan

  • 30

    Jan

  • 05

    Feb

  • 07

    Feb

  • 12

    Feb

  • 13

    Feb

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.